1. Which of the following is TRUE regarding the use of docetaxel in patients with metastatic castrate-resistant prostate cancer (mCRPC)?

2. _____________________________ is a newer, second-generation anti-androgen that is approved for treating metastatic castrate-resistant prostate cancer in patients who have previously received docetaxel.

3. LW is a 57-year-old man with metastatic castrate-resistant prostate cancer who has not had an orchiectomy. He has disease progression and metastasis after initial treatment with a luteinizing hormone-releasing hormone (LHRH) antagonist, and he has now been prescribed abiraterone. Which of the following must he also receive?

4. Adverse events of abiraterone that require regular monitoring include:

5. Sipuleucel-T is approved by the US Food and Drug Administration for use in men with PC who:

6. MR is a 71-year-old man with metastatic castrate-resistant prostate cancer after prior treatment with prostatectomy, external beam radiation therapy, and androgen deprivation therapy (goserelin). He received first-line treatment with docetaxel but has experienced progression of symptomatic metastatic disease, including recent bone fractures and visceral metastases. Which of the following agents would be MOST appropriate to improve survival for MR?

7. Immune-related response criteria would be most appropriate for use with:

8. In one randomized, controlled clinical trial, the time to a first skeletal-related event was longer with ___________ than with zoledronic acid.

9. Which of the following agents would be MOST appropriate to improve overall survival in a patient with metastatic castrate-resistant prostate cancer with symptomatic bone metastases but without visceral metastases?

10. Zoledronic acid requires dose adjustment based on:

« Return to Activity